Department ofHealth and Human Services HHS

"Patients with SLE need newtreatment options; we hope to be able to help meet that need withLymphoStat-B."Key goals for LymphoStat-B in 2009:Report Phase 3 data from BLISS-52 in July.Report Phase 3 data from BLISS-76 in November.ABthrax(TM): Delivery of 20,000 Doses to U.S. Strategic National StockpileExpected Early in Year; HGS Confident of Receiving $150 Million in 2009 HGS has met every milestone to date under its contract with the U.S.Government and is currently awaiting authorization to begin delivery of 20,000doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile foremergency use in treating inhalation anthrax.The Company has completed theanimal studies necessary to demonstrate the efficacy of ABthrax, the humansafety studies necessary for approval, and the manufacture of all bulk drugnecessary to supply 20,000 doses of ABthrax to the Stockpile.In May 2008,HGS submitted the final data package to the FDA to support authorization ofdelivery.ABthrax is being developed under a contract with the BiomedicalAdvanced Research and Development Authority (BARDA) of the U.S. Department ofHealth and Human Services (HHS)."We believe that ABthrax offers a significant step forward in the treatment ofinhalation anthrax and could play an important role in strengthening America'sarsenal against bioterrorism," said Mr Watkins. "We expect to receiveauthorization to begin delivery to the Strategic National Stockpile early thisyear.We are confident that we will receive at least $150 million in 2009from our $165 million contract with the U.S. Government."Key goals for ABthrax in 2009:Deliver 20,000 doses of ABthrax to the Strategic National Stockpileearly in 2009.Receive at least $150 million in revenue.File a Biologics License Application with the FDA in the secondquarter.Darapladib: GSK Phase 3 Development Program Underway In December 2008, GSK announced initiation of the first pivotal Phase 3clinical trial to evaluate the efficacy of long-term treatment with theinvestigational Lp-PLA2 inhibitor darapladib in men and women with chroniccoronary heart disease.Darapladib was discovered by GSK based on HGStechnology.HGS will receive 10 royalties on worldwide sales if darapladibis commercialized, and has a 20 co-promotion option in North America andEurope.In its announcement, GSK said, "Despite major advances in medical treatment,coronary heart disease remains the leading cause of death worldwide and newapproaches are needed to help reduce this burden to society.GSK isinitiating the large STABILITY trial with darapladib as part of a Phase 3program to determine if this novel medication could improve people's lives byreducing the risk of cardiovascular events."GSK also indicated that it plansto initiate another large event-driven trial with darapladib in late 2009 in apost-ACS (acute coronary syndrome) patient population.MID- AND EARLY-STAGE PIPELINESyncria(R): GSK Update on Phase 3 Development Expected in the First QuarterGSK is developing Syncria (albiglutide) as a treatment for type 2 diabetesmellitus, and has completed a number of clinical studies of Syncria, includinga randomized Phase 2b dose-ranging trial of Syncria in patients with type 2diabetes, which included a comparator arm of patients receiving Byetta(exenatide).HGS expects an update from GSK in the first quarter of 2009regarding Phase 3 development of Syncria.Syncria is a novel long-acting form of GLP-1 (glucagon-like peptide 1) createdby HGS using its proprietary albumin-fusion technology, and licensed to GSK in2004.Syncria is generated from the genetic fusion of human albumin andGLP-1, a peptide hormone that acts throughout the body to help maintain normalblood-sugar levels and to control appetite.HGS is entitled to fees andmilestone payments, some of which have already been received, that couldamount to as much as $183 million, in addition to single-digit royalties onworldwide sales if Syncria is commercialized.Oncology Portfolio:A Key Driver of Future GrowthHGS is investing strategically to expand and advance its oncology portfolioaround its leading expertise in the apoptosis, or programmed cell death,pathway.HGS-ETR1 (mapatumumab) is the most advanced of any product indevelopment that targets the TRAIL apoptosis pathway, and three randomizedchemotherapy combination trials are currently underway to evaluate itspotential in the treatment of advanced multiple myeloma, non-small cell lungcancer, and hepatocellular cancer.In May 2008, HGS initiated dosing in a Phase 1 clinical trial to evaluate thesafety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy inpatients with advanced solid tumors.Results of this study will also helpidentify the recommended dose for Phase 2 trials.The IAP inhibitors are anovel class of compounds that block the activity of IAP (inhibitor ofapoptosis) proteins, thus allowing apoptosis to proceed and causing the cancercells to die.When IAP proteins are over-expressed in cancer cells, they canhelp cancer cells resist apoptosis and resume growth and proliferation.FINANCIAL GUIDANCEDuring his presentation to the JPMorgan Healthcare Conference, Mr. Watkinswill present the following guidance regarding the financial results expectedby HGS for the full years 2008 and 2009:HGS expects 2009 net cash burn of less than $25 million, compared withapproximately $245 million in 2008.Revenue is expected to increase to $250 million or higher in 2009,from$48 million in 2008.This includes at least $150 million from sale of 20,000 doses ofABthrax.HGS expects cash and investments at year-end 2009 to totalapproximately$340 million, compared with approximately $365 million at the end of2008.PRESENTATION TO BE WEBCASTMr.

Watkins' presentation to the 27th Annual JPMorgan Healthcare Conferencewill be webcast and may be accessed at The presentation isscheduled to begin on January 14, 2009 at 7:30 AM Pacific or 10:30 AM Easterntime.Investors interested in listening to the live webcast should log onbefore the presentation begins to download any software required.The archiveof the presentation will be available for several days following the event.About Human Genome SciencesThe mission of HGS is to apply great science and great medicine to bringinnovative drugs to patients with unmet medical needs.The HGS clinicaldevelopment pipeline includes novel drugs to treat hepatitis C, lupus,inhalation anthrax, cancer and other immune-mediated diseases.The Company'sprimary focus is rapid progress toward the commercialization of its two keylead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C andLymphoStat-B(R) (belimumab) for lupus.Phase 3 clinical trials of both drugsare ongoing.ABthrax(TM) (raxibacumab) is in late-stage development for the treatment ofinhalation anthrax, and the Company is awaiting authorization to begin thedelivery of 20,000 doses of ABthrax to the Strategic National Stockpile undera contract entered into with the U.S. Government in June 2006.HGS also hasthree drugs in clinical development for the treatment of cancer, including twoTRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor ofapoptosis) proteins.In addition, HGS has substantial financial rights tocertain products in the GSK clinical development pipeline.For more information about HGS, please visit the Company's web site at professionals and patients interested in clinical trialsof HGS products may inquire via e-mail to or bycalling HGS at (301) 610-5790, extension 3550.HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarksof Human Genome Sciences, Inc.Safe Harbor Statement This announcement contains forward-looking statements within the meaning ofSection 27A of the Securities Act of 1933, as amended, and Section 21E of theSecurities Exchange Act of 1934, as amended.The forward-looking statementsare based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject tocertain risks and uncertainties that are difficult to predict.Actual resultsmay differ materially from these forward-looking statements because of theCompany's unproven business model, its dependence on new technologies, theuncertainty and timing of clinical trials, the Company's ability to developand commercialize products, its dependence on collaborators for services andrevenue, its substantial indebtedness and lease obligations, its changingrequirements and costs associated with facilities, intense competition, theuncertainty of patent and intellectual property protection, the Company'sdependence on key management and key suppliers, the uncertainty of regulationof products, the impact of future alliances or transactions and other risksdescribed in the Company's filings with the Securities and ExchangeCommission.In addition, the Company will continue to face risks related toanimal and human testing, to the manufacture of ABthrax and to FDA concurrencethat ABthrax meets the requirements of the ABthrax contract.If the Companyis unable to meet the product requirements associated with the ABthraxcontract, the U.S. government will not be required to reimburse the Companyfor the costs incurred or to purchase any ABthrax doses.Existing andprospective investors are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of today's date. Human GenomeSciences undertakes no obligation to update or revise the informationcontained in this announcement whether as a result of new information, futureevents or circumstances or otherwise.SOURCEHuman Genome Sciences, Inc.Media:Jerry Parrott, Vice President, Corporate Communications,1-301-315-2777, or Investors:Tim Barabe, Senior Vice President and ChiefFinancial Officer, 1-301-315-1780, both of Human Genome Sciences. So far this year, we have seen the Lakers and Celtics make an early argument for the league’s best, while the Magic and Nuggets are only a step behind.

However, not every team is simply performing consistently with their preseason expectations, and a handful of players have really stepped up and proved the doubters wrong 1. The Milwaukee Bucks: While I’m not quite ready to buy a Brandon Jennings jersey just yet, I do like the aggressiveness he brings to a below average team playing without their All-Star shooting guard, Michael Redd.The 20-year-old Jennings is averaging 18.4 points a game, to go along with four assists and a steal, as well as shooting 40 percent from behind the arc. This comes while playing less minutes than most starting point guards. This level of production is surprising from a guy that came off the bench to average five points a game for Italian League team Lottomatica Roma.Andrew Bogut is also playing well, averaging 14 points and nine boards, while Hakim Warrick is contributing 12 points a game. As a pure shooter with a career average of 20 points per game, Redd stretches the defense and will allow Jennings more opportunities to drive to the basket.